Kimberly-Clark Elects Joseph Romanelli to its Board of Directors
Kimberly-Clark (NYSE: KMB) announced the election of Joseph Romanelli to its board of directors, expanding the board from 12 to 13 members. Romanelli currently serves as president of Human Health International for Merck & Co. (MSD), where he oversees 75-plus markets outside the U.S. and leads a team of 14,000 colleagues. Prior to his current role at MSD, which began in 2022, he was CEO of JiXing Pharmaceuticals and held various strategic and operational positions at MSD and Schering-Plough over 25 years.
Kimberly-Clark (NYSE: KMB) ha annunciato l'elezione di Joseph Romanelli nel suo consiglio di amministrazione, aumentando il numero dei membri da 12 a 13. Romanelli attualmente ricopre il ruolo di presidente di Human Health International per Merck & Co. (MSD), dove supervisiona più di 75 mercati al di fuori degli Stati Uniti e guida un team di 14.000 colleghi. Prima del suo attuale ruolo in MSD, iniziato nel 2022, è stato CEO di JiXing Pharmaceuticals e ha occupato diverse posizioni strategiche e operative in MSD e Schering-Plough nel corso di 25 anni.
Kimberly-Clark (NYSE: KMB) anunció la elección de Joseph Romanelli para su junta directiva, ampliando la junta de 12 a 13 miembros. Romanelli actualmente se desempeña como presidente de Human Health International para Merck & Co. (MSD), donde supervisa más de 75 mercados fuera de EE. UU. y lidera un equipo de 14,000 colegas. Antes de su papel actual en MSD, que comenzó en 2022, fue CEO de JiXing Pharmaceuticals y ocupó varias posiciones estratégicas y operativas en MSD y Schering-Plough durante 25 años.
킴벌리-클락 (NYSE: KMB)은 조셉 로마넬리(Joseph Romanelli)를 이사회에 선출했다고 발표하며 이사회 구성원을 12명에서 13명으로 확대했습니다. 로마넬리는 현재 머크(Merck & Co., MSD)의 국제 인체 건강 부문 사장으로 활동하며 미국 외 75개 이상의 시장을 관리하고 14,000명 이상의 동료를 이끌고 있습니다. 2022년 현재 MSD에서의 역할 이전에는 지싱 제약(JiXing Pharmaceuticals)의 CEO로 재직했으며, 25년 동안 MSD 및 셔링-플라우(Schering-Plough)에서 다양한 전략적 및 운영적 직책을 맡았습니다.
Kimberly-Clark (NYSE: KMB) a annoncé l'élection de Joseph Romanelli à son conseil d'administration, portant le nombre de membres à 13 contre 12 auparavant. Romanelli occupe actuellement le poste de président de Human Health International chez Merck & Co. (MSD), où il supervise plus de 75 marchés en dehors des États-Unis et dirige une équipe de 14 000 collaborateurs. Avant son rôle actuel chez MSD, qu'il a commencé en 2022, il a été PDG de JiXing Pharmaceuticals et a occupé plusieurs postes stratégiques et opérationnels chez MSD et Schering-Plough pendant 25 ans.
Kimberly-Clark (NYSE: KMB) gab die Wahl von Joseph Romanelli in seinen Vorstand bekannt und erweiterte die Anzahl der Mitglieder von 12 auf 13. Romanelli ist derzeit Präsident von Human Health International bei Merck & Co. (MSD), wo er über 75 Märkte außerhalb der USA betreut und ein Team von 14.000 Mitarbeiterinnen und Mitarbeitern leitet. Vor seiner derzeitigen Position bei MSD, die 2022 begann, war er CEO von JiXing Pharmaceuticals und hatte über 25 Jahre lang verschiedene strategische und operative Positionen bei MSD und Schering-Plough inne.
- Board expansion adds expertise in global healthcare and international markets
- New director brings extensive leadership experience from major pharmaceutical companies
- Strategic addition aligns with company's Powering Care strategy
- None.
"Joe Romanelli is an outstanding addition to the Kimberly-Clark Board of Directors," said Mike Hsu, chairman and chief executive officer of Kimberly-Clark. "As we advance our Powering Care strategy, we will benefit from Joe's global leadership experience and his expertise in using leading-edge science to save and improve lives around the world."
Mr. Romanelli has served as president of Human Health International for MSD, a global healthcare company that develops and manufactures medicines, vaccines, biologic therapies, and animal health products, since 2022. In this role, he oversees MSD's 75-plus markets outside of the
About Kimberly-Clark
Kimberly-Clark (NYSE: KMB) and its trusted brands are an indispensable part of life for people in more than 175 countries. Fueled by ingenuity, creativity, and an understanding of people's most essential needs, we create products that help individuals experience more of what's important to them. Our portfolio of brands, including Huggies, Kleenex, Scott, Kotex, Cottonelle, Poise, Depend, Andrex, Pull-Ups, GoodNites, Intimus, Plenitud, Sweety, Softex, Viva and WypAll, hold No. 1 or No. 2 share positions in approximately 70 countries. We use sustainable practices that support a healthy planet, build strong communities, and ensure our business thrives for decades to come. We are proud to be recognized as one of the World's Most Ethical Companies(R) by Ethisphere for the fifth year in a row and one of Fortune's Most Innovative Companies in America in 2024. To keep up with the latest news and to learn more about the company's 150-year history of innovation, visit the Kimberly-Clark website.
[KMB-F]
View original content:https://www.prnewswire.com/news-releases/kimberly-clark-elects-joseph-romanelli-to-its-board-of-directors-302303461.html
SOURCE Kimberly-Clark Corporation
FAQ
When did Joseph Romanelli join Kimberly-Clark's (KMB) board of directors?
How many directors are now on Kimberly-Clark's (KMB) board after Romanelli's election?
What is Joseph Romanelli's current position outside of Kimberly-Clark (KMB)?
